Market Access What the low impact of Humira biosimilars teaches us about d... Almost everyone seems to agree that drug prices are too high.
Patients Challenges and opportunities with plasma-derived therapies This newest pharmaphorum podcast welcomes Takeda's Dr Kristina Allikmets.
Patients CinCor Pharma: A small pharma’s journey to acquisition In this week's podcast, pharmaphorum welcomes Marc de Garidel, CEO of CinCor Pharma.
Digital Sponsored AI trends in 2023 AI in pharma is trending toward a moment of maturity, reliability, and scalability.
Digital Solving problems in pathology data, with Nathan Buchbinder Jonah Comstock chats with Nathan Buchbinder, co-founder and chief product officer at Proscia.
Patients How Moderna kept diversity in mind amid vaccine development In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
News Regenxbio's Duchenne gene therapy clears phase 3 hurdle Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
